- Book
- March 2015
- 352 Pages
- Book
- October 2013
- 624 Pages
- Book
- February 2012
- 496 Pages
- Book
- September 2010
- 424 Pages
- Book
- March 2010
- 512 Pages
- Book
- January 2010
- 576 Pages
- Book
- February 2020
- 1152 Pages
- Book
- December 2020
Global

Hepatocellular Carcinoma (HCC) is a type of cancer that originates in the liver. It is the most common form of liver cancer and is the third leading cause of cancer-related deaths worldwide. HCC is typically diagnosed in individuals with underlying liver diseases such as cirrhosis, hepatitis B or C, and non-alcoholic fatty liver disease. Treatment options for HCC include surgery, radiation therapy, chemotherapy, and targeted therapy.
The oncology market for HCC is highly competitive, with a number of companies offering treatments and therapies. These include AbbVie, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche, and Takeda. Additionally, there are a number of smaller companies that are developing novel therapies for HCC, such as Aduro Biotech, ArQule, and Oncoceutics. Show Less Read more